Stemeasy Biotechnology cooperates with Manheng Weipin to advance the clinical translation of 3D bioprinting

　　2019-05-24 At 10:00 in the morning, Shanghai Weipin Information Technology Co., Ltd., a wholly-owned subsidiary of Shanghai Manheng Digital Technology Co., Ltd., and Stemeasy Biotechnology signed a strategic cooperation agreement in the conference hall of Huaxiayuan (Shanghai) Cell Genetic Engineering Co., Ltd. , to jointly promote the research and achievement transformation of bio-3D printing technology in medical clinical direction.

Guest lineup

Zhang Xinbo (General Manager)

Shanghai Weipin Information Technology Co., Ltd.

Chen Huimin (General Manager)

Jiangyin Stemeasy Biotechnology Co., Ltd.

Zhu Hao (General Manager)

Huaxia Yuan Cell Genetic Engineering Co., Ltd.

Shanghai Manheng Digital Technology Co., Ltd., as the general agent of the world-renowned bioprinter envisionTEC 3D-Bioplotter in Greater China, has rich experience in software development, biological 3D printing equipment and process research.

Dr. Chen Huimin, Chief Scientist and CEO of Jiangyin Steyi Biotechnology Co., Ltd., graduated from Harvard Medical School. He is a top expert in the clinical application of stem cells and bioprinting in China. He was the Chief Scientist of GSK China R&D Center. Dr. Chen and his colleagues The bio-3D printing materials and stem cell-related products developed by the team are at the international leading level.

The cooperation between the two parties aims to make full use of their respective advantageous resources to create an integrated and comprehensive solution ranging from clinical-grade 3D printing bio-ink, stem cells, bio-3D printing equipment and materials, printing process support to bio-3D printing GMP standard workshop design and consultation. .